MAPKs represent novel therapeutic targets for gastrointestinal motility disorders

Table 1 MEK1/2 or p38MAPK inhibitors in ongoing clinical trials

Inhibitor		Sponsor	Phase	Study title	Status
MEK1/2 inhibiors
AZD6244		AstraZeneca	Phase II	Randomised study to compare the efficacy of AZD6244 vs TMZ	In progress
		National Cancer Centre, Singapore	Phase I/II	AZD6244 and sorafenib in advanced hepatocellular carcinoma	In progress
		University of Oxford	Phase II	Docetaxel with or Without AZD6244 in melanoma (DOC-MEK)	In progress
		Massachusetts General Hospital	Phase II	AZD6244 in cancers with BRAF mutations	In progress
Other than listed above, almost 20 clinical trials are in progress.
GDC0973		Genentech	Phase I	A study of relative bioavailability and food effect study of GDC-0973 in healthy subjects	Completed
		Genentech	Phase I	Study of GDC-0973/XL518 in patients with solid tumors	In progress
RDEA119		Ardea Biosciences, Inc	Phase I/II	RDEA119 and sorafenib combination dose escalation study	In progress
GSK1120212		GlaxoSmithKline	Phase I	Investigate safty, pharmacokinetics and pharmacodynamics of GSK2118436 & GSK1120212	In progress
		GlaxoSmithKline	Phase I	A study of the GSK MEK inhibitor GSK1120212 and everolimus in cancer subjects	In progress
Other than listed above, 10 clinical trials are in progress.
p38MAPK inhibitors
VX-702		Vertex Pharmaceuticals Incorporated	Phase II	A study in rheumatoid arthritis with an investigational oral p38MAP kinase inhibitor VX-702	Completed
		Vertex Pharmaceuticals Incorporated	Phase II	Phase 2 clinical study in RA with an investigational oral p38 MAP kinase inhibitor VX-702	Completed

Information was obtained from ClinicalTrials.gov (http://clinicaltrials.gov/ct2/home)